Thinc Pharmaceuticals

Thinc is a Netherlands-based biotechnology company specializing in the discovery and development of small molecule therapeutics that target RNA-binding proteins (RBPs). Founded as a spin-off from the Netherlands Cancer Institute (NKI) and the Oncode Institute, the company focuses on oncology, particularly hematological malignancies like Acute Myeloid Leukemia (AML). Thinc's proprietary platform identifies RBPs that act as critical nodes in cancer cell survival, allowing for the development of highly selective inhibitors. The company is backed by prominent life science investors including Forbion and Gilde Healthcare. Their approach represents a novel frontier in precision medicine by modulating post-transcriptional gene regulation.